Stifel initiates Beam Therapeutics [BEAM] at Hold rating with $84 price target
Stifel launched its Beam Therapeutics [BEAM] rating to the equivalent of Hold and assigned the price target of $84, in a research note dated 2021-01-06. That figure represents around a -0.08% premium from where the company’s shares closed on Tuesday. Some new analysts also started their coverage, with Wedbush’s analysts assigning the shares to “an […]
